Inovio Pharmaceuticals (INO) Stock: Running For The Top On Clinical Data

Inovio Pharmaceuticals INO Stock NewsInovio Pharmaceuticals Inc (NASDAQ: INO) is having an overwhelmingly strong start to the trading session in the pre-market hours after releasing new clinical data. The data came from the company’s PENNVAX®-GP, an HIV vaccine that’s showing some promising results. Of course, the clinical update led to excitement among investors, sending the stock on a run for the top. Today, we’ll talk about:

  • The data;
  • what we’re seeing from the stock; and
  • what we’ll be watching for with regard to INO ahead.

INO Runs For The Top On HIV Vaccine News

As mentioned above, Inovio Pharmaceuticals is having an incredibly strong start to the trading session in the pre-market hours after announcing news with regard to PENNVAX®-GP. In a press release issued early this morning, the company announced that the treatment maintained durable and robust immune responses at month 12. This proved to be a full six months after the last dose in the Phase 1 clinical trial.

PENNVAX®-GP is an incredibly promising candidate. Previous data reported by INO shows that the treatment elicited the highest overall levels of immune response rates ever demonstrated in a human study assessing an HIV vaccine. With a combination of four HIV antigens designed to generate both antibody and T-cell responses, the vaccine seems to be a promising course of action to both vaccinate against, and treat, HIV. In a statement, Dr. J. Joseph Kim, President and CEO at INO, had the following to offer:

We are truly pleased to see these robust and durable immune response data, which are among the highest ever responses we’ve seen with an HIV vaccine, and they are remarkably consistent with our recent data reported from our Ebola, Zika and MERS clinical trials in terms of demonstrating nearly 100% vaccine response rates with a very favorable safety profile. Furthermore, our newer and more tolerable intradermal vaccine delivery device showed that we can elicit very high immune responses at a much lower dose. We look forward to further advancing PENNVAX-GP into later-stage clinical development with our partners and collaborators.

What We’re Seeing From The Stock 

One of the first lessons that we learn when we start to dabble in the market is that the news causes moves. In this particular case, the news surrounding Inovio Pharmaceuticals proved to be overwhelmingly positive. HIV is a pressing issue in the medical community, and this data suggests that there may be a vaccine on the horizon. So, it’s no surprise that excited investors are sending the stock upward. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (8:47), INO is trading at $5.23 per share after a gain of $0.50 per share (10.57%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on INO. In particular, we’ll continue to follow the company’s progress with regard to PENNVAX®-GP as well as the rest of its robust pipeline. Nonetheless, we’ll keep an eye on the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Leave a Comment